Added 13 days ago Drug news

CHMP recommends Kromeya (adalimumab biosimilar) for the treatment of certain inflammatory and autoimmune disorders.- Fresenius Kabi

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...

Added 19 days ago Drug news

Pfizer and Eli Lilly report results of Phase III study of tanezumab for moderate-to-severe osteoarthritis (OA) pain.

Pfizer Inc. and Eli Lilly and Company announced positive top-line results from a Phase III study evaluating tanezumab 2.5 mg...

Added 24 days ago Drug news

Phase I/Phase III trial of ABP 798 (rituximab biosimilar) meets primary endpoint in rheumatoid arthritis.- Amgen + Allergan

Amgen and Allergan announced positive top-line results from a Phase I/ Phase III study evaluating the pharmacokinetics, efficacy and safety...

2018 update of the EULAR recommendations for the management of Behçet’s syndrome

These updated, evidence-based recommendations are intended to help physicians caring for patients with BS.

Added 7 months ago

EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice

These are the first EULAR recommendations providing up-to-date guidance for the role of imaging in the diagnosis and monitoring of patients with (suspected) LVV.

Added 7 months ago

Lyme disease

This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment.

Added 8 months ago

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.

The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with...

Added 5 months ago

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Objectives: Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial.

Added 5 months ago

Cause-specific mortality in patients with psoriasis and psoriatic arthritis.

Objective: This retrospective cohort study evaluated the risk and leading causes of mortality in patients with PsO/PsA.

Added 5 months ago

Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide

This is a multi-center, randomized, double-blind, parallel group, active comparator controlled trial to evaluate the efficacy and safety of a single injection of Cingal for the relief of joint pain in subjects with OA of the knee.

Added 7 months ago

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).

Added 7 months ago

A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY)

This is a randomized, double-blind study comparing ABT-494 monotherapy to Methotrexate (MTX) monotherapy in MTX-naïve subjects with moderately to severely active rheumatoid arthritis.

Added 7 months ago